TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10595648
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (usual diet without any supplement)
Study: 8932555
Drug: Control (delayed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (delayed treatment)
Study: 7041935
Drug: 160 mg
Normalized name: nadolol 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160 mg long acting (LA) propranolol
Study: 7041935
Drug: Carbimazole therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbimazole therapy
Study: 6377221
Drug: Oral diuretics
Normalized name: Diabetic Tussin EX Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral diuretics (chlorothiazide, 20 mg/kg/dose and spironolactone, 1.5 mg/kg/dose, given twice daily)
Study: 6377221
Drug: Oral diuretics
Normalized name: Diabetic Tussin EX Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral diuretics
Study: 31563947
Drug: Basal diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal diet top‐dressed with 19 g of the DFM (PROB)
Study: 22795099
Drug: 35 mg
Normalized name: papain 35 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35 mg soy extract daily for 24 weeks
Study: 22795099
Drug: 70 mg
Normalized name: silybin 70 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 70 mg soy extract daily for 24 weeks
Study: 22795099
Drug: 35 mg
Normalized name: papain 35 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35 mg soy extract after 6 months
Study: 22795099
Drug: 70 mg
Normalized name: silybin 70 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 70 mg soy extract after 6 months
Study: 22795099
Drug: 35 mg
Normalized name: papain 35 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35 mg soy extract in patients with high bone turnover after 6 months
Study: 22795099
Drug: 70 mg
Normalized name: silybin 70 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 70 mg soy extract in patients with high bone turnover after 6 months
Study: 18806043
Drug: IV infusion
Normalized name: IV INFUSION SET (WINTHROP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion of phenylephrine and ephedrine combined in a 100% phenylephrine ratio
Study: 18806043
Drug: IV infusion
Normalized name: IV INFUSION SET (WINTHROP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion of phenylephrine and ephedrine combined in a 75% phenylephrine ratio
Study: 18806043
Drug: IV infusion
Normalized name: IV INFUSION SET (WINTHROP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion of phenylephrine and ephedrine combined in a 50% phenylephrine ratio
Study: 18806043
Drug: IV infusion
Normalized name: IV INFUSION SET (WINTHROP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion of phenylephrine and ephedrine combined in a 25% phenylephrine ratio
Study: 18806043
Drug: IV infusion
Normalized name: IV INFUSION SET (WINTHROP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion of phenylephrine and ephedrine combined in a 0% phenylephrine ratio (100% ephedrine)
Study: 15758912
Drug: Allopurinol (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol (600 mg) administered orally at 15 and 3 hours before ERCP
Study: 15758912
Drug: Allopurinol (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol (600 mg)
Study: 11803347
Drug: Autologous blood
Normalized name: Banked autologous blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous blood injection (10-20 ml) beneath the staple line
Study: 10411851
Drug: Enalapril 10
Normalized name: enalapril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 10 mg BID
Study: 10411851
Drug: Losartan 25
Normalized name: LOSARTAN 25MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 25 mg BID
Study: 10411851
Drug: Hoe‐140 (bradykinin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hoe‐140 (bradykinin antagonist) after enalapril
Study: 10411851
Drug: Hoe‐140 (bradykinin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hoe‐140 (bradykinin antagonist) after losartan
Study: 9395384
Drug: Daily primaquine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily primaquine
Study: 7769294
Drug: Daily doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily doxycycline
Study: 7769294
Drug: Weekly mefloquine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly mefloquine
Study: 7769294
Drug: Daily vitamin
Normalized name: Daily Vitamin Liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily vitamin alone
Study: 2178964
Drug: Inhaled salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled salbutamol (0.15 mg.kg‐1 x 2; 30 min apart) (n = 87)
Study: 2178964
Drug: Intravenous salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous salbutamol (5 micrograms.kg‐1) (n = 89)
Study: 2178964
Drug: Theophylline (3‐6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (3‐6 mg.kg‐1) infused i.v. 60 min after salbutamol treatment
Study: 6776300
Drug: Orally administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally administered zomepirac sodium at 100 mg
Study: 6776300
Drug: Orally administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally administered zomepirac sodium at 200 mg
Study: 6776300
Drug: IM administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: IM administered morphine sulfate at 8 mg
Study: 28269449
Drug: Implantable gastric
Normalized name: gastric mucins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implantable gastric electric stimulator with automatic daily activity compliance reporting
Study: 22430968
Drug: PA-824 50
Normalized name: PAS
DrugBank: Aminosalicylic acid (DB00233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PA-824 50 mg
Study: 22430968
Drug: PA-824 100
Normalized name: PAS
DrugBank: Aminosalicylic acid (DB00233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PA-824 100 mg
Study: 22430968
Drug: PA-824 150
Normalized name: PAS
DrugBank: Aminosalicylic acid (DB00233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PA-824 150 mg
Study: 22430968
Drug: PA-824 200
Normalized name: PAS
DrugBank: Aminosalicylic acid (DB00233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PA-824 200 mg
Study: 18848765
Drug: Subcutaneous (SQ)
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (SQ) Acthar Gel (20 units)
Study: 18848765
Drug: Subcutaneous (SQ)
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (SQ) Acthar Gel (80 units)
Study: 18848765
Drug: Intramuscular (IM)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (IM) Acthar Gel (20 units)
Study: 18848765
Drug: Intramuscular (IM)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (IM) Acthar Gel (80 units)
Study: 17449974
Drug: Er,Cr:YSGG laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Er,Cr:YSGG laser therapy combined with SRP
Study: 11122543
Drug: Argatroban (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Argatroban (100 microg/kg bolus plus 3 microg/kg/min infusion for 72 hours)
Study: 11122543
Drug: Heparin (5000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (5000 U intravenous bolus, 1000 U/h infusion)
Study: 9352988
Drug: Chronic vasodilator
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic vasodilator therapy
Study: 9352988
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of vasodilators
Study: 8441105
Drug: Procedure A
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Procedure A (two fractional doses after removal from ventilator)
Study: 8441105
Drug: Procedure B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procedure B (two fractional doses through a neonatal suction valve without removal from ventilator)
Study: 8441105
Drug: Procedure C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procedure C (four fractional doses during removal from ventilator)
Study: 28259274
Drug: Routine injection
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine injection (no topical spray)
Study: 21658093
Drug: Suspension formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suspension formulation of omeprazole in 8.4% sodium bicarbonate
Study: 21658093
Drug: MUPS® formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: MUPS® formulation of omeprazole disintegrated in water
Study: 10930970
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group (medicine review and education programme)
Study: 10930970
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group (medicine education)
Study: 8222684
Drug: Selective digestive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective digestive decontamination (oral antibiotics: polymyxin E, tobramycin, and amphotericin B)
Study: 28065465
Drug: Gefitinib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gefitinib plus metformin
Study: 29030864
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium 3% gel
Study: 18412566
Drug: Aged and
Normalized name: AGS-499
DrugBank: AGS-499 (DB18058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aged and menopaused receiving hormonal replacement therapy
Study: 14594941
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with supportive care to control non-hematological adverse events (nausea/vomiting, anorexia, diarrhea)
Study: 10919591
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF) 1 g twice daily (n=34)
Study: 10919591
Drug: Azathioprine (AZA)
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azathioprine (AZA) 2 mg/kg (n=30)
Study: 10919591
Drug: Dose reduction
Normalized name: Rebetron Combination Package for Rebetol Dose Reduction, Intron A 6,000,000 UNT/ML Multi-Dose Vial / 42 Rebetol Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose reduction of MMF to 500 mg twice daily
Study: 10919591
Drug: Dose reduction
Normalized name: Rebetron Combination Package for Rebetol Dose Reduction, Intron A 6,000,000 UNT/ML Multi-Dose Vial / 42 Rebetol Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose reduction of AZA to 1.0 mg/kg
Study: 8160596
Drug: Optimal medical
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal medical therapy (amiodarone)
Study: 3168726
Drug: Sorbinil (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorbinil (250 mg/day)
Study: 27978511
Drug: Daprodustat 4
Normalized name: daprodustat 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daprodustat 4 mg
Study: 27978511
Drug: Daprodustat 6
Normalized name: daprodustat 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daprodustat 6 mg
Study: 27978511
Drug: Daprodustat 8
Normalized name: daprodustat 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daprodustat 8 mg
Study: 27978511
Drug: Daprodustat 10
Normalized name: daprodustat
DrugBank: Daprodustat (DB11682)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Daprodustat 10 mg
Study: 27881458
Drug: High-dose (HD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose (HD) group: 2 + 2 mg 17B-estradiol/day orally
Study: 27881458
Drug: Low-dose (LD)
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose (LD) group: 2 mg 17B-estradiol/day orally and placebo
Study: 27027075
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) with an 830 nm gallium-aluminum-arsenic laser at 30 mW
Study: 19654505
Drug: d-amphetamine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-amphetamine (2.5 mg/70 kg)
Study: 19654505
Drug: d-amphetamine (5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-amphetamine (5.0 mg/70 kg)
Study: 19654505
Drug: d-amphetamine (10.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-amphetamine (10.0 mg/70 kg)
Study: 19654505
Drug: diazepam (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: diazepam (2.5 mg/70 kg)
Study: 19654505
Drug: diazepam (5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: diazepam (5.0 mg/70 kg)
Study: 19654505
Drug: diazepam (10.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: diazepam (10.0 mg/70 kg)
Study: 2185814
Drug: 5% dextrose
Normalized name: LMD with 5% Dextrose
DrugBank: D-glucose (DB01914)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% dextrose water 10 ml kg‐1 orally about 4 h before operation
Study: 2185814
Drug: No oral
Normalized name: Beano Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: No oral intake after midnight (fasted group)
Study: 286492
Drug: BCG-CWS and
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG-CWS and chemotherapy as maintenance therapy
Study: 286492
Drug: BCG-CWS therapy
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG-CWS therapy
Study: 23895984
Drug: Topical mitomycin
Normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical mitomycin C (MMC) application
Study: 22004765
Drug: Tanezumab 25
Normalized name: tanezumab
DrugBank: Tanezumab (DB12335)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tanezumab 25 μg/kg
Study: 22004765
Drug: Tanezumab 100
Normalized name: tanezumab
DrugBank: Tanezumab (DB12335)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tanezumab 100 μg/kg
Study: 15362523
Drug: Chinese traditional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese traditional medicine, indomethacin, and three kinds of antibacterial agents
Study: 15362523
Drug: Chinese traditional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese traditional medicine and indomethacin only
Study: 15362523
Drug: Antibacterial agents
Normalized name: Dermoplast Antibacterial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibacterial agents
Study: 11375357
Drug: Nateglinide (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nateglinide (120 mg before three meals daily, n = 51)
Study: 11375357
Drug: Glyburide (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glyburide (5 mg q.d. titrated to 10 mg q.d. after 2 weeks, n = 50)
Study: 9225934
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human erythropoietin (rHuEPO) 141 U/kg subcutaneously, 6 injections between Days -21 and -7, along with 200 mg of iron saccharose complex intravenously at each visit.
Study: 9225934
Drug: Placebo, along
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, along with 200 mg of iron saccharose complex intravenously at each visit.
Study: 7943463
Drug: Low-dose TRH
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose TRH (0.5 mg) administered 5 minutes after ECT session 3 or 4
Study: 3148039
Drug: 10 days
Normalized name: AlleRx 10-day Dose Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 days of intravenous nutrition
Study: 30310698
Drug: DHA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA supplementation (1g nutraceutical formulation)
Study: 21029154
Drug: Oral health-related
Normalized name: Healthy Mama Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral health-related quality of life
Study: 16178295
Drug: Standardised treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardised treatment only
Study: 1463177
Drug: Propofol induction
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol induction (1.5-2.5 mg/kg)
Study: 1463177
Drug: Additional propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Additional propofol (0.5 mg/kg/30s)
Study: 29772833
Drug: High protein
Normalized name: Vital High Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: High protein human milk fortifier (HMF) providing 1.8 g protein per 100 mL expressed breast milk (EBM)
Study: 29772833
Drug: Standard human
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard human milk fortifier (HMF) providing 1 g protein per 100 mL expressed breast milk (EBM)
Study: 25376396
Drug: Low-dose behavioral
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose behavioral treatment (16 sessions)
Study: 25376396
Drug: Moderate-dose behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-dose behavioral treatment (32 sessions)
Study: 25376396
Drug: High-dose behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose behavioral treatment (48 sessions)
Study: 23118302
Drug: Rosuvastatin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin therapy (20 mg/d) for 12 months
Study: 17170721
Drug: High-dose methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methotrexate (HD MTX) at 1.5 g/m(2)/2 weeks x 6 in Lower-risk group
Study: 17170721
Drug: High-dose methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methotrexate (HD MTX) at 8 g/m(2)/2 weeks x 4 in Intermediate-risk group
Study: 17170721
Drug: Low-dose methotrexate
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose methotrexate (LD MTX) at 25 mg/m(2)/week in Lower-risk group
Study: 17170721
Drug: Low-dose methotrexate
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose methotrexate (LD MTX) in Intermediate-risk group
Study: 17170721
Drug: High-dose methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methotrexate (HD MTX)
Study: 24415567
Drug: Pregabalin 150
Normalized name: pregabalin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin 150 mg/d
Study: 11361045
Drug: Onion supplement
Normalized name: ONION
DrugBank: Onion (DB10548)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Onion supplement (100 mg quercetin)
Study: 11361045
Drug: Quercetin‐4'‐O‐glucoside (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quercetin‐4'‐O‐glucoside (100 mg quercetin)
Study: 11361045
Drug: Buckwheat tea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buckwheat tea (200 mg quercetin)
Study: 11361045
Drug: Quercetin‐3‐O‐rutinoside (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quercetin‐3‐O‐rutinoside (200 mg quercetin)
Study: 7805372
Drug: Low-dose combined
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose combined oral contraceptives (OCs)
Study: 3170454
Drug: Thioridazine high
Normalized name: Thioridazine
DrugBank: Thioridazine (DB00679)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thioridazine high dose (2.50 mg/kg per day)
Study: 3170454
Drug: Thioridazine low
Normalized name: Thioridazine
DrugBank: Thioridazine (DB00679)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thioridazine low dose (1.25 mg/kg per day)
Study: 3170454
Drug: Thioridazine (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thioridazine (both doses)
Study: 20564914
Drug: COPD concurrent
Approvals — FDA: no, EMA: no, PMDA: no
Description: COPD concurrent with T2D
Study: 18460663
Drug: Combination pill
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination pill containing 2.5 mg of folic acid, 50 mg of vitamin B6, and 1 mg of vitamin B12
Study: 16368822
Drug: Lidocaine 1.5
Normalized name: LIDOCAINE 1.5%/EPI 1:200000 INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 1.5 mg/kg IV
Study: 10602739
Drug: Oral fluoroquinolones
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral fluoroquinolones (general)
Study: 8615305
Drug: Rotational atherectomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotational atherectomy (RA) with adjunctive balloon angioplasty
Study: 1730079
Drug: Desferrioxamine B
Normalized name: Deferrioxamine B
DrugBank: Deferoxamine (DB00746)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desferrioxamine B (100 mg/kg per day by continuous 72‐hour subcutaneous infusions)
Study: 6397729
Drug: L-5-HTP (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-5-HTP (100 mg/day)
Study: 29529618
Drug: Systemic IV
Normalized name: Vaginal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic IV administration of 1 g vancomycin
Study: 20197425
Drug: LABA step‐up
Approvals — FDA: no, EMA: no, PMDA: no
Description: LABA step‐up (100 microg of fluticasone plus 50 microg of a long‐acting beta‐agonist twice daily)
Study: 20197425
Drug: LTRA step‐up
Approvals — FDA: no, EMA: no, PMDA: no
Description: LTRA step‐up (100 microg of fluticasone twice daily plus 5 or 10 mg of a leukotriene‐receptor antagonist daily)
Study: 20197425
Drug: ICS step‐up
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICS step‐up (250 microg of fluticasone twice daily)
Study: 1345826
Drug: Fine-bore silicone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fine-bore silicone catheter (23 G, 15 cm)
Study: 1345826
Drug: Teflon catheter
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teflon catheter (20 G, 3.2 cm)
Study: 6234505
Drug: Megavitamin therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Megavitamin therapy (3 g of niacinamide, 1.2 g of calcium pantothenate, 0.6 g of pyridoxine, and ascorbic acid)
Study: 6234505
Drug: Megavitamin therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Megavitamin therapy
Study: 31152740
Drug: Pantoprazole (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole (40 mg daily)
Study: 23873118
Drug: Dexmedetomidine (0.1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (0.1, 0.15, and 0.15 mcg/kg)
Study: 18278193
Drug: Clopidogrel 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 600 mg loading dose (LD) followed by 75 mg/d maintenance dose (MD) for 10 days
Study: 18278193
Drug: Prasugrel 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel 60 mg LD followed by 10 mg/d MD for 10 days
Study: 18278193
Drug: Prasugrel 10
Normalized name: prasugrel 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel 10 mg/d MD for 11 days
Study: 29502548
Drug: THC (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: THC (10 mg) administered orally